pp-236 Inhalation powder
Dossier type
US CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: Pulmonary Arterial Hypertension (PAH), PH-ILD, IPF / Clinical stage: Phase 2b / Modality: Small molecule prostanoid analogue / Mechanism & Target: Prostanoid receptor agonist for pulmonary vasodilation / Route & form: Inhaled powder / Differentiation: Once-daily inhaled formulation vs TID IV/SC standard
Manufacturer #4408
| Clinical-stage radiopharmaceutical company specializing in copper-based theranostic agents. Develops proprietary chelation technology for targeted cancer imaging and therapy in oncology. Advances Phase 3 programs across neuroendocrine and prostate cancer indications. |
None